New Criteria for the Clinical Diagnosis of Hyperandrogenism in Polycystic Ovarian Syndrome and the Risk of Overdiagnosis

    June 2019 in “ Revista brasileira de ginecologia e obstetrícia ”
    José Maria Soares-Jr, Marcos Felipe Silva de Sá, Edmund Chada Baracat
    Image of study
    TLDR Using only hyperandrogenism to diagnose PCOS can lead to overdiagnosis.
    The document discussed the issue of excess body hair in women, known as hirsutism, which often affects their femininity and self-esteem. Hirsutism is typically linked to hyperandrogenism, but this association is not always present. In 30-50% of women with mild hirsutism, elevated androgen levels were not detected, highlighting the risk of overdiagnosis when using hyperandrogenism as a sole criterion for diagnosing conditions like Polycystic Ovarian Syndrome (PCOS).
    Discuss this study in the Community →

    Research cited in this study

    2 / 2 results

    Related Community Posts Join

    6 / 24 results

      community DHT levels after 4 weeks of Fina and 8 weeks of Fina + 4 weeks of Duta

      in Update  36 upvotes 5 years ago
      The user reported early stage diffuse hair thinning and increased DHT levels after 4 weeks on Finasteride and 8 weeks on Finasteride plus 4 weeks on Dutasteride, despite the medications being authentic and stored properly. They are considering increasing their Dutasteride dosage due to the lack of side effects and are unsure if the treatment is helping their hair.

      community AA and Hirsutism but T levels are normal

      in Female  8 upvotes 3 years ago
      27-year-old female experiences aggressive hair thinning and hirsutism despite normal testosterone levels. Spironolactone and 2% minoxidil were ineffective; high DHEA sulfate levels may be the cause.

      community No, Finasteride as a treatment for MPB was not an "accident"

      in Research/Science  105 upvotes 3 years ago
      Finasteride was intentionally developed to treat BPH and later approved for male pattern baldness (MPB) due to its 5AR inhibition effects. The delay in MPB approval was due to concerns about off-label use for female hirsutism and the prioritization of treating a more debilitating condition.

      community Coegin Pharma to release Follicopeptide (FOL005) by Q2 2025

      in Treatment  117 upvotes 2 months ago
      Follicopeptide (FOL005) by Coegin Pharma will launch as a cosmetic hair growth treatment by Q2 2025, showing similar efficacy to finasteride. Users discuss the benefits and skepticism of releasing hair loss treatments as cosmetics rather than drugs.

      community Does low HGH leading to hairloss?

      in Research/Science  13 upvotes 9 months ago
      The user experiencing diffuse hair loss is using various treatments including RU58841, finasteride, minoxidil with tretinoin, anti-hair loss shampoo, and microneedling, and is considering adding peptides TB500, BPC157, and GHK-Cu. They have low growth hormone levels and are questioning its impact on hair loss, while another user suggests androgenic alopecia and androgens are likely the main cause of hair loss.

    Related Research

    4 / 4 results